Method of generating tumor-specific T cells
AssigneeCase Western Reserve University
InventorsJulian Kim, Kevin Choong, Hallie Graor, Mei Zhang, John Ammori, Anthony Visioni
Life of this patent
Estimating the term…
Abstract
A method of treating cancer in a subject includes contacting an enriched population of T-cells obtained from cancer or tumor draining lymph nodes ex-vivo with: an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and optionally a VEGF inhibitor and/or an IL-2 receptor agonist, at amounts effective to activate and expand the T-cells and administering the activated and expanded T-cells to the subject.
Claims21
A method of treating cancer in a subject, the method comprising:
- obtaining tumor draining lymph node (TDLN) tissue from the subject wherein the TDLNs drain a tumor and/or a cancer metastasis of the subject;
- obtaining an enriched population of tumor-specific T-cells from the TDLN tissue, wherein tumor-specific T-cells are specific to the tumor and/or cancer metastasis of the subject;
- activating and expanding tumor-specific T-cells by contacting the enriched population of tumor-specific T-cells ex-vivo with:
- an anti-CD3 antibody, an anti-CD28 antibody,
- and/or functional fragments thereof, a VEGF inhibitor and optionally an IL-2 receptor agonist, at amounts effective to activate and expand the tumor-specific T-cells;
- and
- administering the activated and expanded tumor-specific T-cells to the subject.
The method of 1, wherein the activated and expanded tumor-specific T-cell population is washed, and resuspended in a solution that does not include a VEGF-inhibitor for administration into the subject.
A method of treating pancreatic cancer in a subject, the method comprising:
- obtaining pancreatic cancer draining lymph node (PDLN) tissue from the subject;
- obtaining an enriched population of tumor-specific T-cells from the PDLN tissue, wherein the tumor-specific T-cells are specific to pancreatic cancer of the subject;
- activating and expanding tumor-specific T-cells by contacting the enriched population of tumor-specific T-cells ex-vivo with:
- an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, a VEGF inhibitor and optionally an IL-2 receptor agonist, at amounts effective to activate and expand the tumor-specific T-cells;
- and
- administering the activated and expanded tumor-specific T-cells to the subject.
The method of 12, wherein the activated and expanded tumor-specific T-cell population is washed, and resuspended in a solution that does not include a VEGF-inhibitor for administration into the subject.
The method of 1, wherein the activated and expanded tumor-specific T-cell population is washed, and resuspended in a solution that does not include a VEGF-inhibitor for administration into the subject.
Dependencies are inferred from the claim text.